Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Approved
Approved. Cetrorelix is the active ingredient in Cetrotide, an FDA-approved drug product for specific indications. Approval is specific to the product, indication, and route.
Drugs@FDA: Cetrotide (NDA 021197)By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 5/5. 789 PubMed citations indexed.
Cetrorelix (Cetrotide) is a synthetic decapeptide GnRH antagonist that competes directly with native GnRH for binding to pituitary membrane receptors, producing immediate graded suppression of
What the literature studies
Metabolic Research
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
Local allergic reactions (erythema, itching, swelling) at injection sites are more common with cetrorelix than with GnRH agonists; systemic allergic reactions including anaphylaxis
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.